Zum Hauptinhalt springen

Rekrutierende Studien

AARON

An Open-Label Phase II Study of Relatlimab (BMS-986016) With Nivolumab (BMS-936558) in Combination With 5-Azacytidine for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older Acute Myeloid Leukemia Patients

MOSAIC

Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia

PALOMA

Primary comparison of Liposomal Anthracycline based treatment versus conventional care strategies before allogeneic stem cell transplantation in patients with higher risk MDS and oligoblastic AML

PEMAZA

MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse

RELAX

Phase-I/II Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax

TEAM

Targeting Epigenetic Therapy Resistance in AML With Bortezomib: A Multi-centre Matched Threshold Crossing Phase II Approach